Abstract
Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial. Methods: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives. Conclusion: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.
Original language | English (US) |
---|---|
Pages (from-to) | 135-144 |
Number of pages | 10 |
Journal | Journal of Comparative Effectiveness Research |
Volume | 3 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- Phase III
- blood and bone marrow transplant
- cost-effectiveness
- randomized controlled trial
ASJC Scopus subject areas
- Health Policy